Bipolar Disorder

The experts weighed in on a wide variety of psychiatric issues for the December 2022 issue of Psychiatric Times.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

The novel atypical antipsychotic is already FDA-approved for the treatment of schizophrenia in adults.

New research indicates worsened air quality leads to increased depressive symptoms in patients with bipolar disorder.

"This study served as a sobering reminder of the significant frequency of this disfiguring and sometimes disabling adverse effect, which can be irreversible."

Does childhood trauma affect outcomes in bipolar disorder? Researchers analyzed the impact of childhood trauma on outcomes in outpatients with bipolar disorder treated with lithium or quetiapine in a randomized clinical trial.

From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.

The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.

In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.

From the cardiac adverse effects of lithium to the road to over-the-counter naloxone, here are highlights from the week in Psychiatric Times.

A survivor of bipolar disorder shares some close calls and cautionary lessons.

When should you monitor electrocardiograms in patients taking lithium?

How did patients with BDI and obesity fare in new research looking at quality of life issues?

From the relationship between psychotic disorders and dementia risk to the major differences between bipolar I and bipolar II, here are highlights from the week in Psychiatric Times.

An expert discusses key differences and some ways to avoid missing the appropriate diagnosis in these patient populations.

Lithium and the kidneys: Researchers analyzed the effects of withdrawal of chronic lithium therapy on renal function.

Catch up on the latest bipolar disorder research featured in Psychiatric Times.

"Despite this new study and the need for further research, the best recommendation at this time regarding lithium in patients with bipolar disorder who are suicidal would be to consider it a worthwhile option."

From the at-home ketamine experience to the Wit v United Behavioral Health reversal, here are highlights from the week in Psychiatric Times.

Researchers performed a nationwide cohort study of the use of calcium-channel blockers and adenosine modulators and risk of hospitalization in bipolar disorder.

From older age bipolar disorder to the relationship between antidepressants and emotional numbing, here are highlights from the week in Psychiatric Times.

What treatments are available for those with older age bipolar disorder?

Between 1980 and 1998, the relative frequency of late-onset bipolar disorder increased from 1% to 11%. How can you best assess for this condition?

From historic USPSTF draft screening recommendations to the need for novel treatments for bipolar depression, here are highlights from the week in Psychiatric Times.

In this CME article, learn more about the rationale for considering novel treatments for patients with bipolar depression.

The FDA has accepted the NDA for aripiprazole 2-month, ready-to-use, long-acting injectable.

Researchers performed a systematic review and meta-analysis of the prevalence of bipolar disorder and associated mood episodes in perinatal women.

In this CME article, examine how current DSM nosology defines the proper method of assessing a mixed-episode patient and which diagnostic labels to give them based on their presenting symptomatology.

This diet was associated with significant reductions in variability of symptoms in patients with bipolar disorder.

Cardiometabolic risk factors for suicide? Researchers investigated associations between obesity/metabolic syndrome and suicidality in patients with bipolar disorder.